Figure 10 : The effects of imeglimin, sitagliptin and repaglinide on insulin secretion in response to glucose were investigated in non-diabetic Wistar rats and diabetic N0STZ rats, using the hyperglycaemic clamp as described in Methods. In addition to basal (T0) levels, two levels of hyperglycaemia were studied. In the non-diabetic Wistar rats, imeglimin increased insulin secretion versus controls at the highest glycaemic level only. In the diabetic N0STZ rats, imeglimin increased insulin secretion versus controls at all levels of glycaemia, and at an increased magnitude to that of the other two anti-diabetic agents (**P<0.01; ***P<0.001 compared with controls).